Kathy brings 20+ years of experience in drug development, with demonstrated expertise in defining global regulatory strategies, leading regulatory filings and interactions with regulatory agencies, and facilitating regulatory transition of development projects to commercial stage.
Prior to joining OncoNano Kathy served as Vice President, Regulatory Affairs at ZS Pharma, which started as a development stage biopharmaceutical company, focusing on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver, and metabolic diseases. The company was subsequently acquired by AstraZeneca for $2.7 billion. Kathy received her BS in Microbiology from Oklahoma State University
She has also held leadership roles with Alcon Laboratories and Encysive Pharmaceuticals.